Switching is a decision initiated by clinicians, to exchange one medicine for another medicine with the same therapeutic intent25, a practice which is considered safe for biological medicines25,26. Over a decade of experience in Europe, from thousands of patients, consistently shows that switching between new versions of the originator biologic, or between a reference biologic and a biosimilar, does not affect safety, efficacy or immunogenicity19.
European Public Assessment Reports (EPARs) available on the European Medicines Agency (EMA) website, offer substantial evidence for the safety of a switch, and can be viewed here.